A practical reference on actin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-13. Anything still debated is marked as such rather than presented as settled.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
During Bukele's September 2019 meeting with Trump, Bukele called on Trump to promote legal migration in an effort to combat illegal immigration and to maintain the United States' temporary protected status (TPS) policy for Salvadorans living in the United States. The following month, Bukele confirmed that the United States would continue TPS for Salvadorans. In February 2021, Biden refused to meet Bukele when he arrived unannounced in Washington, D.C. to meet him. Bukele did not attend the 9th Summit of the Americas in June 2022 due to frustration with the U.S. government's allegations of corruption and human rights abuses by his government. Some Democratic Party members have been critical of Bukele's government, and members of the Republican Party have supported him and his policies. Bukele and Norma Torres, a member of the U.S. Congress representing California's 35th congressional district, engaged in an April 2021 argument on Twitter about illegal immigration at the United States' southern border. Torres accused Bukele in November 2022 of interfering in that month's 35th congressional district election by endorsing Republican challenger Mike Cargile. In January 2024, fourteen Democratic members of Congress sent a letter to Biden about Bukele's "authoritarian" actions. Meanwhile, Republican congressmen such as Tom Cotton, Matt Gaetz, and Marco Rubio have praised Bukele's policies on crime. The second Trump administration considers Bukele to be an important ally in mitigating immigration to the U.S. from Central America.
=== Eli Vance === Dr. Eli Vance (voiced by Robert Guillaume in Half-Life 2 and its episodes and by James Moses Black in the prequel Half-Life: Alyx) is a physicist, researcher, and Harvard University graduate who worked with Gordon Freeman at Black Mesa. He wears a prosthetic that replaces his left leg beneath the knee, which was lost when he was attacked by a Bullsquid while helping Dr. Isaac Kleiner climb over a wall into a Combine city; this is not from any canon sources yet many fans and Marc Laidlaw, the story writer of the Half-Life franchise, have since accepted it. He is Alyx Vance's father; his late wife, Azian, died in the aftermath of the resonance cascade. The leader of the Lambda Resistance, Dr. Vance was the first human being to make peaceful contact with the Vortigaunt species and thus the "first collaborator", quickly persuading the alien race to ally with humanity against the Combine invasion of Earth. In Episode Two, Eli Vance works at the White Forest base before being killed by a Combine Advisor. The 2020 VR game Half-Life: Alyx, which takes place between the events of Half-Life and Half-Life 2, focuses on Eli and Alyx Vance as they fight against the Combine's occupation of Earth. As a result of the events of the game, his death is prevented, albeit at the cost of his daughter Alyx becoming an unwilling agent of the G-Man. Upon learning the truth, Eli seeks to rescue her.
=== Conservation of mass in mixing calculations === 2H and 1H are stable isotopes. Therefore, the 2H/1H ratio of a pool containing hydrogen, remains constant as long as no hydrogen is added or removed, a property known as conservation of mass. When two pools of hydrogen A and B mix with molar amounts of hydrogen mA and mB, each with their own starting fractional abundance of deuterium (FA and FB), then the fractional abundance of the resulting mixture is given by the following exact equation:
=== Toronto-area hotel expenses scandal === Between 2023 and 2026, Toronto MPP Stan Cho expensed $16,203 to the Ontario Legislature for hotel stays in Toronto, despite his residence being 5.9 kilometres from the Legislative Assembly. Through his office, Cho issued a comment, stating that "[w]hile these expenses meet the criteria for special circumstances as set out by the Legislative Guide for Member’s expenses, I will be personally reimbursing the legislature for any expense that does not meet the spirit of the policy," before later commenting that "I will be personally reimbursing the legislature for the entire amount of the expenses incurred". Cho faced criticism from the opposition, with New Democratic leader Marit Stiles noting that "[you] can get from Willowdale to Queen’s Park without even changing the subway train". Cho was also directed to repay the expenses by Premier Doug Ford, who told him "[you're] paying back every single penny — that’s not the way we operate, simple as that". He delivered his letter of resignation, effective immediately, to Premier Ford during the morning of July 17, 2026. Cho stated he will continue to serve as a Member of Provincial Parliament (MPP) for Willowdale. Other PC MPPs also expensed Toronto hotel stays using the policy, which Ford announced plans to reform.
Sources: en.wikipedia.org
=== Early career === Casey made her professional debut in 2013 defeating Kelly Warren by rear naked choke. Casey was then submitted by Pearl Gonzalez by armbar in her second fight. After the loss Casey signed with the Middle Eastern promotion PXC before going on a three fight win streak, finishing all of her opponents.
For instance, more public officials are brought within the scope of the directive, and EU member states are required to establish new registries of "beneficial owners" (i.e., those who ultimately own or control each company) which will impact banks. AMLD IV became effective 25 June 2015. On 24 January 2019, the European Commission sent official warnings to ten member states as part of a crackdown on lax application of money laundering regulations. The Commission sent Germany a letter of formal notice, the first step of the EU legal procedure against states. Belgium, Finland, France, Lithuania, and Portugal were sent reasoned opinions, the second step of the procedure which could lead to fines. A second round of reasoned opinions was sent to Bulgaria, Cyprus, Poland, and Slovakia. The ten countries have two months to respond or face court action. The commission had set a 26 June 2017 deadline for EU countries to apply new rules against money laundering and terrorist financing. On 13 February 2019, the Commission added Saudi Arabia, Panama, Nigeria and other jurisdictions to a blacklist of nations that pose a threat because of lax controls on terrorism financing and money laundering. This is a more expansive list than that of FATF.
Sight-threatening CMV retinitis in severely immunocompromised people CMV pneumonitis in bone marrow transplant recipients Prevention of CMV disease in bone marrow and solid organ transplant recipients Confirmed CMV retinitis in people with AIDS (intravitreal implant) It is also used for acute CMV colitis in HIV/AIDS and CMV pneumonitis in immunosuppressed patients. Ganciclovir has also been used with some success in treating Human herpesvirus 6 infections. Ganciclovir has also been found to be an effective treatment for herpes simplex virus epithelial keratitis.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.